Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RET (Rearranged during Transfection) is a receptor tyrosine kinase that plays essential roles in cell proliferation, differentiation, survival, migration, and metabolism. It is the canonical signaling receptor for members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands. Mutations or rearrangements involving RET can lead to constitutive activation or loss-of-function: Gain-of-function mutations are associated with multiple endocrine neoplasia type 2 (MEN2), medullary thyroid carcinoma, papillary thyroid carcinoma. Loss-of-function mutations cause Hirschsprung’s disease due to impaired enteric neuron development.
Tyrosine kinase inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rearranged during Transfection (RET).